AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.
Emory University
Thomas Jefferson University
Cyteir Therapeutics, Inc.
M.D. Anderson Cancer Center
Gilead Sciences
Celgene
Hoffmann-La Roche
Arbeitsgemeinschaft medikamentoese Tumortherapie
Ohio State University Comprehensive Cancer Center
Aptevo Therapeutics
St. Petersburg State Pavlov Medical University
Hoffmann-La Roche
Weill Medical College of Cornell University
St. Petersburg State Pavlov Medical University
Medical College of Wisconsin
Columbia University
St. Petersburg State Pavlov Medical University
Mayo Clinic
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
Swiss Cancer Institute
Seagen Inc.
University of Washington
German CLL Study Group
Ohio State University Comprehensive Cancer Center
Lund University Hospital
National Cancer Institute (NCI)
Johannes Gutenberg University Mainz
University of Alabama at Birmingham
Teva Branded Pharmaceutical Products R&D, Inc.
Kantonsspital Aarau
Teva Branded Pharmaceutical Products R&D, Inc.